Physician profile
Anthony Ciarolla
NPI 1922068881
$9,383.10
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,400 · 2020: $761 · 2021: $951 · 2022: $1,722 · 2023: $1,901 · 2024: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167 · Education: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.21 |
| Education | $381.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $992.94 | 2019-2024 | Opdivo, Opdualag |
| Pfizer INC. | $952.55 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $726.04 | 2019-2023 | |
| Astellas Pharma US INC | $637.29 | 2019-2024 | Xtandi |
| Genentech USA, INC. | $547.33 | 2019-2024 | Tecentriq |
| Janssen Biotech, INC. | $545.00 | 2019-2024 | Darzalex, Imbruvica, Carvykti |
| Astrazeneca Pharmaceuticals LP | $381.46 | 2019-2023 | Enhertu, Lynparza |
| Genzyme Corporation | $327.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $292.84 | 2019-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $292.49 | 2019-2024 | Alunbrig, Iclusig, Ninlaro |
| Incyte Corporation | $277.93 | 2019-2023 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $257.15 | 2019-2024 | |
| Eisai INC. | $246.54 | 2019-2024 | |
| Abbvie INC. | $234.28 | 2019-2024 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $212.48 | 2019-2023 | Imbruvica |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $209.93 | 2019-2024 | Libtayo |
| Lilly USA, LLC | $180.89 | 2019-2022 | |
| Amgen INC. | $160.65 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Seagen INC. | $154.80 | 2019-2023 | Adcetris |
| Celgene Corporation | $149.24 | 2019-2024 | Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.21 | 2019-2023 | Gilotrif |
| Daiichi Sankyo INC. | $144.49 | 2019-2024 | Enhertu |
| Exelixis INC. | $114.01 | 2019-2023 | Cabometyx |
| Sobi, INC | $113.47 | 2022-2024 | |
| Clovis Oncology, INC. | $103.14 | 2019 | |
| Gilead Sciences, INC. | $95.51 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $86.67 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $82.72 | 2020-2023 | Xpovio |
| Sun Pharmaceutical Industries INC. | $76.37 | 2019-2022 | |
| Myovant Sciences INC. | $75.61 | 2021 | |
| Foundation Medicine, INC. | $56.73 | 2019-2023 | Foundationone Liquid Cdx |
| Stemline Therapeutics INC. | $50.27 | 2023 | Orserdu |
| Epizyme, INC. | $45.00 | 2021 | |
| Secura Bio, INC. | $40.42 | 2022 | |
| Morphosys, US INC. | $34.99 | 2022 | |
| Viiv Healthcare Company | $31.85 | 2024 | Dovato |
| Teva Pharmaceuticals USA, INC. | $31.33 | 2019 | |
| Beigene USA, INC. | $31.23 | 2023 | Brukinsa |
| Taiho Oncology, INC. | $28.82 | 2022 | |
| Glaxosmithkline, LLC. | $27.10 | 2022 | |
| Tesaro, INC. | $27.04 | 2019 | |
| Immunogen, INC. | $26.19 | 2023 | Elahere |
| Mirati Therapeutics, INC. | $26.13 | 2023 | Krazati |
| Amag Pharmaceuticals, INC. | $25.08 | 2020 | |
| Array Biopharma INC | $23.94 | 2021 | |
| Verastem, INC. | $23.49 | 2020 | |
| Dova Pharmaceuticals | $18.00 | 2019 | |
| Eusa Pharma (US) LLC | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ciarolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.